Clinical Trial Update: Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating interleukin-12 and interleukin-2 in patients with mycosis fungoides and Sezary syndrome. The study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycosis Fungoides
• Sezary Syndrome

Drugs mentioned

• Interleukin-12 (interleukin-12)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome | Phase 1, Phase 2 | Status: TERMINATED